The global medical technology market is expanding rapidly as ageing populations and rising healthcare needs drive demand. Asia is increasingly important to that growth. Fortune Business Insights project mainland China’s medical-device market to reach US$82 billion by 2032, while a CB Insights study says Asia now accounts for 43 per cent of the global drug-development pipeline, up from 28 per cent five years ago.
Strategically positioned within the Guangdong-Hong Kong-Macao Greater Bay Area (GBA), Hong Kong sits within the Guangdong-Hong Kong-Macao Greater Bay Area and the Shenzhen-Hong Kong-Guangzhou innovation cluster, ranked first globally. Building on its strengths in capital access and connectivity to the Chinese Mainland, Hong Kong is emerging as a compelling launchpad for global medical device makers.
Hong Kong as a scaling platform
Tech startups needs capital for scaling. Hong Kong’s capital market strengths remain as important as ever, with the city ranked as the world’s second-largest biotech IPO fundraising hub. Its role increasingly includes helping companies advance from research and clinical validation towards commercialisation and overseas expansion.
The CB Insights study gave Hong Kong a Mosaic score of 370, ranking first in Asia and fifth globally, reflecting a dense concentration of scale-ready, highly investable ventures.
Favourable policies tailored to life and health tech development are strengthening another part of the proposition. The Greater Bay Area International Clinical Trial Institute, the forthcoming Hong Kong Centre for Medical Products Regulation, the primary evaluation mechanism and Chapter 18A of Hong Kong’s listing rules support companies across the development pipeline, from clinical work and regulatory approval to access to capital.
The difficulty for these companies is that success rarely rests on the technology alone. Clinical evidence has to be gathered, regulatory requirements understood, manufacturing arranged and distributors or customers secured. That is how the I&T ecosystem orchestrator comes in to connect more of those capabilities in one place.
HKSTP connects the life-and-health tech ecosystem
Hong Kong Science and Technology Parks Corporation (HKSTP), the city’s largest innovation and technology (I&T) ecosystem, is home to more than 2,500 companies from 26 countries and regions and has supported 14 unicorns. Its life-and-health cluster alone comprises more than 400 companies.
With life and health tech as one of the strategic clusters, HKSTP offers end-to-end incubation – spanning laboratory research, regulatory guidance, expert networks, and funding – to empower life and health tech startups at every stage of growth.
Global groups including Merck from Germany, together with Roche, Amgen and Boehringer Ingelheim Venture Fund, participate as co-incubators, bringing industry knowledge and international networks closer to startups.

HKSTP’s Biomedical Technology Support Centre (BSC) spans 22,000 sq ft and is equipped with more than 300 instruments. Other world-class facilities include Medical Device and Testing Lab, and biobank & histopathology Services, allowing innovators to speed up the journey of drug discovery and clinical development.

Global expansion: HKSTP’s MEDICA debut
“As an ecosystem orchestrator, HKSTP connects capital, talent, infrastructure, industry partners and global market opportunities across the life-and-health innovation journey,” said HKSTP chief executive officer Terry Wong.
“Going global to demonstrate innovation breakthroughs and facilitate cross-border collaboration can help international innovators access Asia’s clinical capabilities and market scale, while helping Hong Kong and mainland companies reach overseas markets.” Wong added.

Taking Hong Kong medtech to MEDICA
Following its BIO 2026 outreach in San Diego, HKSTP is making its MEDICA debut in Düsseldorf this month with over 20 park companies and university spin-offs exhibiting at the Hong Kong pavilion, showcasing the ecosystem’s breakthrough innovations and cross-border collaboration capabilities to European healthcare leaders and partners.

At MEDICA, HKSTP will sign MoUs with leading European healthcare cluster Medical Valley EMN and Germany-based Kalms Consulting. Medical Valley and HKSTP plan to facilitate 10 company introductions each year and organise an annual innovation event to support Europe-Asia market access, while Kalms Consulting will advise HKSTP ventures on European regulation and market entry.
Park companies are also pursuing their own cross-border partnerships. Orange Biotech, an HKSTP-incubated developer of CRISPR-based diagnostic platforms, will work with Hungarian medical-device manufacturer CorLab on European expansion. Pushkang will partner with Egypt’s Keen Diagnostic Partners to commercialise its MS200 Automated Chemistry Analyzer across the region.
AusMed will stage the European launch of its Ketometrics breath analyser, and Dymind will unveil its upgraded, CE-marked DH-8000 haematology analysis workstation, with HKSTP CEO Terry Wong witnessing the signings.
World’s first innovation ready to travel
Agilis Robotics is an example of a Hong Kong venture combining local research with international clinical connections. Its Intilume™ System has enabled the world’s first robot-assisted en-bloc resection of a bladder tumour in a human trial.
First-in-human results have been published in European Urology following work with Hong Kong’s Prince of Wales Hospital, while preclinical research on robot-assisted Endoscopic Submucosal Dissection in the gastrointestinal tract has also been conducted with Cleveland Clinic in the United States, with results published in Surgical Endoscopy.
Agilis has raised US$34 million to date, setting a funding record within HKSTP’s Incu-Bio programme. It is attending MEDICA for the first time as it seeks greater exposure among European clinicians and academic institutions.
Other world-first developments include Hugemed’s single-use ureterorenoscope, Yuanhua Robotics’ five-in-one orthopaedic surgical platform and a PEEK joint from iBone Health backed by almost five years of clinical follow-up data.

Global recognition for Hong Kong medtech
International recognition has also come through competitions. Excalipoint Therapeutics and GenEditBio took first and second place at BioJapan’s SHIC Fast Track, while OncoImmunostics, Advanced Micro Integrations and Rare Power received the Grand, Gold and Silver awards respectively at the 2026 Washington Innovation & Entrepreneurship Competition.
Looking ahead: a two-way gateway for global medtech
As HKSTP marks its 25th Anniversary, the flagship HKSTP Life & Health Tech Global Conference is set to launch in May 2027, bringing together global leaders across science, healthcare, investment, industry, and regulation to explore LHT technologies and partnerships shaping the future of healthcare.
For overseas companies seeking a foothold in Asia, Hong Kong can serve as an entry point. European medtech groups can tap research, clinical partners, capital and GBA connections through the city, while Hong Kong and mainland ventures heading overseas can access regulatory expertise, distributors and commercial partners through the same network.
